Background To date only few real-world setting studies evaluated apremilast efficacy in psoriatic arthritis (PsA). Enthesitis and dactylitis are difficult-to-treat features of PsA leading to disability affecting quality life. Objectives The aims this study is evaluate the leed enthesitis index (LEI) dactlitis (DAI) at 6 12 month patients on treatment with apremilast. Methods All consecutive tre...

Psoriatic arthritis (PsA) is a multi-faceted disease. It may involve not only the joints in the sense of arthritis , but also the tendons surrounding the joints, leading to swelling of whole digits (dactylitis), or it may lead to inflammation of the entheses (enthesitis). PsA is considered one of the seronegative spondyloarthropathies, because it may also affect the axial system (spondylar-thri...

Enthesitis, the infl ammation involving the insertion of tendons, ligaments and joint capsule is a characteristic sign and hallmark of several rheumatic diseases in both adult and paediatric patients. The change in the perception of enthesitis (ie, its growing sig-nifi cance as a clinicopathological entity) is best refl ected in the new European League Against Rheumatism (EULAR) recommendations...

Background: IgG4-related disease (IgG4-RD) is a fibroinflammatory disorder which can affect almost any tissue in the body. We describe challenging case of IgG4-RD reflects great heterogeneity this disease. Objectives: A 49-year-old Mauritanian gentleman was referred to Rheumatology with chronic progressive symmetrical synovitis affecting upper and lower limbs. He had no features suggestive spon...

Background Enthesitis and dactylitis are associated with greater disease activity reduced quality of life. Results from the phase 3 randomized, placebo-controlled KEEPsAKE 1 2 studies ( NCT03675308 ; NCT03671148 ) risankizumab in active PsA showed resolution enthesitis 150 mg vs placebo at week 24. Objectives This post hoc analysis evaluated improvements patient-reported outcomes (PROs) among p...

Background Guselkumab (GUS), an IL-23p19 inhibitor, has demonstrated efficacy in psoriatic arthritis (PsA) across key Group for Research and Assessment of Psoriasis (PsO) Psoriatic Arthritis (GRAPPA)-recommended domains [1,2] . Skin disease enthesitis have been identified as manifestations with earlier response times than others [3] Objectives In this analysis we: (a) Determined whether early s...